GlobeNewswire
-
Rakovina Therapeutics Announces Extension of Non-Brokered Private Placement
12/03/2026 -
Koelis annonce, à l’occasion du Congrès de l’EAU 2026, des innovations technologiques destinées à optimiser les flux de travail de biopsie par fusion IRM et à soutenir le développement de la thérapie focale dans la prise en charge du cancer de la prostate
12/03/2026 -
Aeroflow Health Earns 2026 Great Place To Work Certification™
12/03/2026 -
SK pharmteco annonce la certification CGMP de son site de production de vecteurs viraux à échelle commerciale en France
12/03/2026 -
Sanofi: Information concerning the total number of voting rights and shares - February 2026
12/03/2026 -
Sanofi: Informations relatives au nombre de droits de vote et d'actions - FEVRIER 2026
12/03/2026 -
EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as of March 11, 2026
12/03/2026 -
EssilorLuxottica: Nombre total de droits de vote et d’actions composant le capital social au 11 mars 2026
12/03/2026 -
Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons
12/03/2026 -
HealthEx Partners with Microsoft to Bring Consumers’ Personal Health History to Copilot Health
12/03/2026 -
Chemed Corporation to Present at the Oppenheimer 36th Annual Healthcare Conference
12/03/2026 -
Serotonin Centers Introduces New Medical Longevity Model for the Fitness Industry
12/03/2026 -
Cloudcure Launches Companion App to Close Clinical Adherence Gap in Metabolic Health
12/03/2026 -
Polaryx Therapeutics Deepens Engagement with the Krabbe Disease Community Through Scientific and Patient Advocacy Events
12/03/2026 -
CDT Notes Sarborg Expansion into Rare Disease Signature Intelligence
12/03/2026 -
Celularity Reiterates Strategic Commercialization Partnership with NEXGEL Focused on Building Biomaterials Franchise with Established Commercial Products and New 510(k) Pathway Product Opportunities
12/03/2026 -
ORAGENICS INITIATES PHASE IIA CLINICAL TRIAL SITE ACTIVATION
12/03/2026 -
Ultragenyx Announces Positive 36-Week Data from Phase 3 Study of DTX301 AAV8 Gene Therapy for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency
12/03/2026 -
Orchestra BioMed Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update
12/03/2026
Pages